BMJ 2001;322:579 ( 10 March )

Papers

Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial

Urs Eriksson, physician, ^a Burkhard Seifert, statistician, ^b Andreas Schaffner, professor. ^a

^a Medicine B, University Hospital, University of Zurich, CH-8091 Zurich, Switzerland, ^b Department of Biostatistics, University of Zurich

Correspondence to: U Eriksson, Medicine A, University Hospital, CH-4031 Basel, Switzerland on klinerr{at}usz.unizh.ch

Objective: To test the hypothesis that amphotericin B deoxycholate is less toxic when given by continuous infusion than by conventional rapid infusion.
Design: Randomised, controlled, non-blinded, single centre study.
Setting: University hospital providing tertiary clinical care.
Patients: 80 mostly neutropenic patients with refractory fever and suspected or proved invasive fungal infections.
Intervention: Patients were randomised to receive 0.97 mg/kg amphotericin B by continuous infusion over 24 hours or 0.95 mg/kg by rapid infusion over four hours.
Main outcome measures: Patients were evaluated for side effects related to infusion, nephrotoxicity, and mortality up to three months after treatment. Analysis was on an intention to treat basis.
Results: Patients in the continuous infusion group had fewer side effects and significantly reduced nephrotoxicity than those in the rapid infusion group. Overall mortality was higher during treatment and after three months' follow up in the rapid infusion than in the continuous infusion group.
Conclusion: Continuous infusions of amphotericin B reduce nephrotoxicity and side effects related to infusion without increasing mortality.

---

© BMJ 2001
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Delivering drugs and making the BMJ less boring
BMJ 2001 322: 0. [Full Text] [PDF]

Delivering drugs and making the BMJ less boring
BMJ 2001 322: 0. [Full Text] [PDF]

Continuous infusions of amphotericin B deoxycholate reduce toxicity
BMJ 2001 322: 0. [Full Text]

This article has been cited by other articles:

• Ellis, M., Bernsen, R., Ali-Zadeh, H., Kristensen, J., Hedstrom, U., Poughias, L., Bresnik, M., Al-Essa, A., A. Stevens, D. (2009). A safety and feasibility study comparing an intermittent high dose with a daily standard dose of liposomal amphotericin B for persistent neutropenic fever. J Med Microbiol 58: 1474-1485 [Abstract] [Full text]  
• Odabasi, Z., Karaalp, A., Cermik, H., Mohr, J., Tigen, E. T., Koc, M., Korten, V. (2009). Reduction of Amphotericin B-Induced Renal Tubular Apoptosis by N-Acetylcysteine. Antimicrob. Agents Chemother. 53: 3100-3102 [Abstract] [Full text]  
• Bulpa, P., Dive, A., Sibille, Y. (2007). Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J 30: 782-800 [Abstract] [Full text]  
• Altmannsberger, P., Holler, E., Andreesen, R., Krause, S. W. (2007). Amphotericin B deoxycholate: no significant advantage of a 24 h over a 6 h infusion schedule. J Antimicrob Chemother 60: 180-182 [Full text]  
• van der Voort, P. H. J., Boerma, E. C., Yska, J. P. (2007). Serum and intraperitoneal levels of amphotericin B and flucytosine during intravenous treatment of critically ill patients with Candida peritonitis. J Antimicrob Chemother 59: 952-956 [Abstract] [Full text]  
• Blyth, C. C., Palasanthiran, P., O'Brien, T. A. (2007). Antifungal Therapy in Children With Invasive Fungal Infections: A Systematic Review. Pediatrics 119: 772-784 [Abstract] [Full text]  
• ECHEVARRIA, J., SEAS, C., CRUZ, M., CHAVEZ, E., CAMPOS, M., CIEZA, J., GOTUZZO, E., LLANOS, A. (2006). ORAL REHYDRATION SOLUTION TO PREVENT NEPHROTOXICITY OF AMPHOTERICIN B. Am J Trop Med Hyg 75: 1108-1112 [Abstract] [Full text]  
• Enoch, D. A., Ludlam, H. A., Brown, N. M. (2006). Invasive fungal infections: a review of epidemiology and management options.. J Med Microbiol 55: 809-818 [Abstract] [Full text]  
• Chen, C.-Y., Kumar, R. N., Feng, Y.-H., Ho, C.-H., You, J.-Y., Liao, C.-C., Tseng, C.-H., Mavros, P., Gerth, W. C., Chen, Y.-C. (2006). Treatment outcomes in patients receiving conventional amphotericin B therapy: a prospective multicentre study in Taiwan. J Antimicrob Chemother 57: 1181-1188 [Abstract] [Full text]  
• Lewis, R. E., Wiederhold, N. P., Prince, R. A., Kontoyiannis, D. P. (2006). In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin. J Antimicrob Chemother 57: 288-293 [Abstract] [Full text]  
• Martin, C. A. (2005). Invasive Fungal Infections in the Critically Ill Patient. Journal of Pharmacy Practice 18: 9-17 [Abstract]  
• Kontoyiannis, D. P., Lewis, R. E., Tattevin, P., Bareau, B., Camus, C., Marty, F. M., Lowry, C. M., Schneemann, M., Imhof, A., Danaher, P. J., Jones, B. L., McLintock, L. A., Walsh, T. J., Donowitz, G. R., dePauw, B. E. (2005). Caspofungin versus liposomal amphotericin B for empirical therapy.. NEJM 352: 410-414 [Full text]  
• Peleg, A. Y., Woods, M. L. (2004). Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients. J Antimicrob Chemother 54: 803-808 [Abstract] [Full text]  
• Bellmann, R., Egger, P., Gritsch, W., Bellmann-Weiler, R., Joannidis, M., Kaneider, N., Dunzendorfer, S., Wiedermann, C. J. (2003). Amphotericin B lipid formulations in critically ill patients on continuous veno-venous haemofiltration. J Antimicrob Chemother 51: 671-681 [Abstract] [Full text]  
• Chryssanthou, E., Cars, O., Sjolin, J. (2002). New Automated Method for Determining Postantifungal Effect of Amphotericin B against Candida Species: Effects of Concentration, Exposure Time, and Area under the Curve. Antimicrob. Agents Chemother. 46: 4016-4018 [Abstract] [Full text]  
• Flansbaum, B. E., Huddleston, J. M. (2002). Update in Hospital Medicine. ANN INTERN MED 137: 814-822 [Abstract] [Full text]  
• Maschmeyer, G. (2002). New antifungal agents--treatment standards are beginning to grow old. J Antimicrob Chemother 49: 239-241 [Full text]  
• (2001). ADDITIONAL ARTICLES ABSTRACTED IN ACP JOURNAL CLUB. Evid. Based Med. 6: 163-163 [Full text]  
• (2001). Amphotericin B Infusion: Slower Is Better. JWatch General 2001: 7-7 [Full text]  
• Reichenberger, F., Habicht, J.M., Gratwohl, A., Tamm, M. (2001). Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients. Eur Respir J 19: 743-755 [Abstract] [Full text]  

Rapid Responses:

Read all Rapid Responses

Complications of amphotericin therapy

Mike Dennis
bmj.com, 23 Mar 2001 [Full text]

In response to Dr. Dennis

Eriksson Schaffner
bmj.com, 9 Apr 2001 [Full text]

Adverse effects of rapid versus slow infusion of amphotericin B

Julio Collazos
bmj.com, 28 Jun 2001 [Full text]

Online poll

Find out more >>